ArticleOncoTargets and therapy2019

SMYD2-OE promotes oxaliplatin resistance in colon cancer through MDR1/P-glycoprotein via MEK/ERK/AP1 pathway.

Hailiang Ren et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.